| Literature DB >> 33861442 |
Zinat Heidari1, Marzieh Mohammadi2, Amirhossein Sahebkar3,4,5,6.
Abstract
The novel coronavirus outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was recognized in late 2019 in Wuhan, China. Subsequently, the World Health Organization declared coronavirus disease 2019 (COVID-19) as a pandemic on 11 March 2020. The proportion of potentially fatal coronavirus infections may vary by location, age, and underlying risk factors. However, acute respiratory distress syndrome (ARDS) is the most frequent complication and leading cause of death in critically ill patients. Immunomodulatory and anti-inflammatory agents have received great attention as therapeutic strategies against COVID-19. Here, we review potential mechanisms and special clinical considerations of supplementation with curcumin as an anti-inflammatory and antioxidant compound in the setting of COVID-19 clinical research.Entities:
Keywords: ARDS; COVID-19; Curcuminoids; Inflammation
Mesh：
Substances：
Year: 2021 PMID： 33861442 DOI： 10.1007/978-3-030-64872-5_11
Source DB: PubMed Journal: Adv Exp Med Biol ISSN： 0065-2598 Impact factor: 2.622